PrECOG, LLC.

Quick facts

Phase 3 pipeline

• Arm A: Belantamab Mafodotin · Oncology
  Belantamab mafodotin is an antibody-drug conjugate that targets BCMA on multiple myeloma cells and delivers a cytotoxic payload to kill them.
• Arm B: Daratumumab Hyaluronidase · Oncology
  Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while hyaluronidase enables subcutaneous administration by breaking down hyaluronic acid in subcutaneous tissue.

Phase 2 pipeline

• Induction Venetoclax · Oncology
  BCL-2 inhibitor
• Maintenance Venetoclax
• vandetanib induction
• Vandetanib maintenance

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• PrECOG, LLC. portfolio CI brief
• PrECOG, LLC. pipeline updates RSS